Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Clinical trial NCT05462717 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05462717
Sponsor: Revolution Medicines, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma Advanced Solid Tumor

Start date: 2022-09-19
Primary completion: 2027-03-31
Enrollment: 222

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.